Sirolimus as a new drug to treat RIF patients with elevated Th17/Treg ratio: A double-blind, phase II randomized clinical trial

Ahmadi Majid; Abdolmohamadi-vahid Samaneh; Ghaebi Mahnaz; Dolati Sanam; Abbaspour-Aghdam Sanaz; Danaii Shahla; Berjis Katayoun; Madadi-Javid Rahime; Nouri Zahra; Siahmansouri Homayoon; Babaloo Zohreh; Nouri Mohammad; Yousefi Mehdi

首页> 外文期刊>International immunopharmacology >Sirolimus as a new drug to treat RIF patients with elevated Th17/Treg ratio: A double-blind, phase II randomized clinical trial

【24h】

Sirolimus as a new drug to treat RIF patients with elevated Th17/Treg ratio: A double-blind, phase II randomized clinical trial

机译：西罗莫司作为一种治疗RIF患者的新药物，患有升高的TH17 / TREG比例：双盲，第二期随机临床试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: RIF is clinically defined as the failure of good quality embryos to implant into the uterus following at least three cycles of In Vitro Fertilization/Embryo Transfer (IVF/ET). During human pregnancy, a genetically different fetus is allowed to survive within the uterus despite the maternal recognition of fetal alloantigens. Compared with normal pregnant women, early loss of embryo is associated with systemic lower levels of Treg cells in IVF. Moreover, several lines of evidence have indicated that differentiation of naive T cells into Th17 is deleterious for normal pregnancy and may cause implantation failure. Sirolimus as the most common mTOR (mammalian target of Rapamycin) inhibitor is able to effectively prevent allograft rejection. Here we aimed to evaluate Sirolimus effects on Th17/Treg axis and subsequently on pregnancy outcome.

机译：背景：RIF在临床上定义为良好的质量胚胎在体外施肥/胚胎转移（IVF / ET）中的至少三个循环后植入子宫内植入子宫。在人体怀孕期间，尽管胎儿血管原孕孕母体识别，但仍可在子宫内生存遗传不同的胎儿。与正常孕妇相比，早期的胚胎损失与IVF中的系统性降低的Treg细胞水平有关。此外，几种证据表明，对于正常妊娠，幼稚T细胞对Th17的差异是有害的，并且可能导致植入失败。作为最常见的MTOR（哺乳动物的雷帕霉素靶标）抑制剂的西罗莫司能够有效地防止同种异体移植物排斥。在这里，我们旨在评估对Th17 / Treg轴的西罗莫司效应，随后对妊娠结局进行评估。

著录项

来源
《International immunopharmacology》 |2019年第2019期|共10页
作者
Ahmadi Majid; Abdolmohamadi-vahid Samaneh; Ghaebi Mahnaz; Dolati Sanam; Abbaspour-Aghdam Sanaz; Danaii Shahla; Berjis Katayoun; Madadi-Javid Rahime; Nouri Zahra; Siahmansouri Homayoon; Babaloo Zohreh; Nouri Mohammad; Yousefi Mehdi;
展开▼
作者单位

Tabriz Univ Med Sci Immunol Res Ctr Tabriz Iran;

Tabriz Univ Med Sci Stem Cell Res Ctr Tabriz Iran;

Tabriz Univ Med Sci Stem Cell Res Ctr Tabriz Iran;

Tabriz Univ Med Sci Stem Cell Res Ctr Tabriz Iran;

Tabriz Univ Med Sci Fac Med Dept Immunol Tabriz Iran;

ACECR Eastern Azerbaijan Branch Gynecol Dept Eastern Azerbaijan ACECR ART Ctr Tabriz Iran;

ACECR Qom Branch Acad Ctr Educ Culture &

Res Qom Iran;

ACECR Eastern Azerbaijan Branch Gynecol Dept Eastern Azerbaijan ACECR ART Ctr Tabriz Iran;

ACECR Qom Branch Acad Ctr Educ Culture &

Res Qom Iran;

Tabriz Univ Med Sci Fac Med Dept Immunol Tabriz Iran;

Tabriz Univ Med Sci Stem Cell Res Ctr Tabriz Iran;

Tabriz Univ Med Sci Stem Cell &

Regenerat Med Inst Tabriz Iran;

Tabriz Univ Med Sci Stem Cell Res Ctr Tabriz Iran;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词
Recurrent implantation failure; Sirolimus; Th17/Treg axis;

机译：复发性植入失败;西罗莫司;Th17 / Treg轴;

相似文献

外文文献
中文文献
专利

1. Sirolimus as a new drug to treat RIF patients with elevated Th17/Treg ratio: A double-blind, phase II randomized clinical trial [J] . Ahmadi Majid, Abdolmohamadi-vahid Samaneh, Ghaebi Mahnaz, International immunopharmacology . 2019,第期

机译：西罗莫司作为一种治疗RIF患者的新药物，患有升高的TH17 / TREG比例：双盲，第二期随机临床试验
2. Human urinary kallidinogenase in treating acute ischemic stroke patients: analyses of pooled data from a randomized double-blind placebo-controlled phase IIb and phase III clinical trial [J] . Dong Yi, Qu Jiazhi, Zhang Zhijun, Neurological Research: An Interdisciplinary Quarterly Journal . 2020,第4期

机译：治疗急性缺血性脑卒中患者的人泌尿基因酶：来自随机双盲安慰剂控制IIB和第III期临床试验的合并数据分析
3. Randomized comparison of a sirolimus-eluting Orsiro stent with a biolimus-eluting Nobori stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian Organization for Randomized Trials with Clinical Outcome VII trial [J] . Jensen Lisette Okkels, Thayssen Per, Maeng Michael, The American heart journal . 2015,第2期

机译：经皮冠状动脉介入治疗的患者西罗莫司洗脱的Orsiro支架与Biolimus洗脱的Nobori支架的随机比较：斯堪的纳维亚随机临床试验组织的临床试验研究基础和研究设计
4. A double-blind, randomized phase II trial of thesafety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adults [C] . Shelly A. McNeil, Scott A. Halperin, Joanne M. Langley, Lancefield International Symposium on Streptococci and Streptococcal Diseases . 2006

机译：一种双盲，随机期II试验，对健康成人的26岁的26岁群体的疫苗疫苗
5. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
6. A double-blind placebo-controlled randomised multicentre proof-of-concept and dose-finding phase II clinical trial to investigate the safety tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2) [O] . Christopher Geven, Alice Blet, Matthijs Kox, 2019

机译：一项双盲安慰剂对照随机多中心概念验证和剂量确定的II期临床试验用于研究败血性休克和肾上腺髓质素浓度升高（AdrenOSS-2）患者中阿德珠单抗的安全性耐受性和疗效
7. Randomized clinical comparison of the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent with the sirolimus-eluting Orsiro stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) X trial [O] . Lars Jakobsen, Evald H Christiansen, Michael Maeng, 2018

机译：用经皮冠状动脉介入治疗的患者双治疗CD34抗体覆盖的西罗莫猴洗脱组合组合的临床比较冠状动脉介入治疗的患者：斯堪的纳维亚组织对临床结果的随机试验的基本原理和研究设计（整理） x试验

Sirolimus as a new drug to treat RIF patients with elevated Th17/Treg ratio: A double-blind, phase II randomized clinical trial

摘要

著录项

相似文献

相关主题

期刊订阅